AR085800A1 - Vacuna de rinitis equina - Google Patents

Vacuna de rinitis equina

Info

Publication number
AR085800A1
AR085800A1 ARP120100823A ARP120100823A AR085800A1 AR 085800 A1 AR085800 A1 AR 085800A1 AR P120100823 A ARP120100823 A AR P120100823A AR P120100823 A ARP120100823 A AR P120100823A AR 085800 A1 AR085800 A1 AR 085800A1
Authority
AR
Argentina
Prior art keywords
strain
identity
erav
equine
erab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP120100823A
Other languages
English (en)
Inventor
Phillip Wayne Hayes
Kristina J Hennessy
Laurent Viel
Andres Diaz-Mendez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica de C V SA
Boehringer Ingelheim Vetmedica Inc
Original Assignee
Boehringer Ingelheim Vetmedica de C V SA
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica de C V SA, Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica de C V SA
Publication of AR085800A1 publication Critical patent/AR085800A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Composiciones inmunogénicas contra virus de rinitis equina, en particular virus de rinitis equina A y B y métodos para su uso y su preparación. Las composiciones inmunogénicas, en formas de realización alternativas, también incluyen otros agentes patógenos de equinos.Reivindicación 1: Una composición inmunogénica caracterizada porque comprende una o varias cepas de inactivados o vivos, atenuados el virus de rinitis equina A (ERAV) o virus de rinitis equina B (ERBV), a) en donde la cepa de ERAV o la cepa de ERAB, antes de la inactivación o atenuación, causa una enfermedad respiratoria detectable en al menos el 50% de caballos seronegativos expuestos a la cepa; y/o b) crecidos en cultivo celular a 106 TCID50/mL o más; y/o, c) cuando se usa como una vacuna en equinos en una dosis de 106 TCID50 o más da como resultado una titulación sérica de al menos 1:112; y/o d) en donde dicha cepa de ERAV comprende una secuencia genómica cuyo transcripto inverso tiene más del 95% de identidad con la SEQ ID Nº 2; y/o e) en donde dicho ERAV codifica una poliproteína con una secuencia de aminoácidos con más del 95% de identidad con la SEQ ID Nº 3; y/o f) en donde dicha cepa de ERBV comprende una secuencia genómica cuyo transcripto inverso tiene más del 95% de identidad con el transcripto inverso de la secuencia genómica de la cepa de ERAB que tiene número de acceso ATCC PTA-11829; y/o g) en donde dicha cepa de ERVB codifica una poliproteína con una secuencia de aminoácidos con más del 95% de identidad con la poliproteína codificada por el genoma de la cepa de ERAB que tiene número de acceso ATCC PTA-11829.
ARP120100823A 2011-03-14 2012-03-13 Vacuna de rinitis equina Pending AR085800A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452390P 2011-03-14 2011-03-14
US201161510226P 2011-07-21 2011-07-21

Publications (1)

Publication Number Publication Date
AR085800A1 true AR085800A1 (es) 2013-10-30

Family

ID=45876924

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100823A Pending AR085800A1 (es) 2011-03-14 2012-03-13 Vacuna de rinitis equina

Country Status (12)

Country Link
US (1) US9187730B2 (es)
EP (2) EP2686012B1 (es)
AR (1) AR085800A1 (es)
AU (2) AU2012229192B2 (es)
BR (2) BR122019023542B1 (es)
CA (2) CA2829226C (es)
ES (2) ES2748555T3 (es)
MA (1) MA35303B1 (es)
MX (1) MX350718B (es)
NZ (1) NZ614147A (es)
TW (1) TW201300537A (es)
WO (1) WO2012125525A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2829226C (en) 2011-03-14 2023-01-03 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine
CA2967532A1 (en) * 2014-11-24 2016-06-02 Intervet International B.V. Inactivated equine influenza virus vaccines
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
US20200323975A1 (en) * 2017-12-04 2020-10-15 Intervet Inc. Vaccination with replicon particles and oil adjuvant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
MXPA03007766A (es) 2001-02-28 2004-03-16 Akzo Nobel Nv Emulsiones inyectables de agua en aceite.
CA2440593A1 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AUPR472501A0 (en) 2001-05-02 2001-05-24 Council Of The Queensland Institute Of Medical Research, The Equine rhinitis a virus antigens
MXPA04000680A (es) 2001-07-27 2004-04-05 Wyeth Corp Vacuna para virus west nile.
ATE359816T1 (de) 2001-10-19 2007-05-15 Acambis Inc Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
JP4683926B2 (ja) 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
EP1664786B1 (en) 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1645283A1 (en) 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1896069B1 (en) 2005-06-24 2013-03-13 Intervet International BV Inactivated chimeric vaccines and related methods of use
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
KR20110126726A (ko) 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
NZ567684A (en) 2005-11-01 2011-06-30 Intervet Int Bv Prime boost vaccine for the protection of equines against equine influenza
US7455842B2 (en) 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
MX2011002071A (es) 2008-08-29 2011-04-05 Boehringer Ingelheim Vetmed Vacuna para el virus del nilo occidental.
CA2829226C (en) 2011-03-14 2023-01-03 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine

Also Published As

Publication number Publication date
US20120237543A1 (en) 2012-09-20
MA35303B1 (fr) 2014-08-01
TW201300537A (zh) 2013-01-01
AU2017201526C1 (en) 2019-10-24
NZ708320A (en) 2016-08-26
AU2012229192B2 (en) 2017-04-20
MX2013010125A (es) 2013-10-07
WO2012125525A3 (en) 2013-02-28
EP2772266B1 (en) 2019-07-31
AU2017201526A1 (en) 2017-03-30
AU2017201526B2 (en) 2019-07-18
BR122019023542B1 (pt) 2022-02-15
ES2748555T3 (es) 2020-03-17
NZ614147A (en) 2015-08-28
CA3018230A1 (en) 2012-09-20
BR112013023354A2 (pt) 2016-12-06
WO2012125525A2 (en) 2012-09-20
BR112013023354B1 (pt) 2022-02-15
EP2686012B1 (en) 2020-12-02
CA2829226A1 (en) 2012-09-20
CA2829226C (en) 2023-01-03
EP2772266A1 (en) 2014-09-03
ES2842595T3 (es) 2021-07-14
EP2686012A2 (en) 2014-01-22
MX350718B (es) 2017-09-14
US9187730B2 (en) 2015-11-17
AU2012229192A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
AR065076A1 (es) Vacuna contra el papilomavirus
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
WO2008039408A3 (en) Live bacterial vaccines for viral infection prophylaxis or treatment
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
MX2009006178A (es) Vacuna contra salmonela.
AR106026A1 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
UY32274A (es) Pestivirus quimericos
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
AR085800A1 (es) Vacuna de rinitis equina
WO2017156511A8 (en) Live attenuated zika virus vaccine
PE20140871A1 (es) COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CO2019013220A2 (es) Virus oncolíticos y método
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
AR103427A1 (es) Vacuna contra la fiebre aftosa
CO6280408A2 (es) Vacuna de virus de la lengua azul y composiciones inmunogenicas procedimientos de uso y procedimeintos de la produccuion de la misma
AR081409A1 (es) PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV)
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
Swati et al. Isolation and phylogenetic characterization of Canine distemper virus from India
CL2023002187A1 (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino
CO2021017322A1 (es) Péptidos inmunogénicos contra el virus distemper canino (cdv)
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella

Legal Events

Date Code Title Description
FC Refusal